Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Recurrence × Congresses as Topic × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Neuroblastoma 2 Gliosarcoma 2 Glioblastoma 2 Ganglioneuroblastoma 2 Wilms Tumor 1 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Thyroid Diseases 1 Thyroid Cancer, Papillary 1 Thoracic Diseases 1 Testicular Neoplasms 1 Teratoma 1 Stomach Neoplasms 1 Stage I Prostate Adenocarcinoma AJCC v7 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Seroma 1 Salivary Gland Neoplasms 1 Rhabdomyosarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Polycystic Ovary Syndrome 1 Parathyroid Neoplasms 1 Parathyroid Diseases 1 Pancreatic Neoplasms 1 Ovarian Germ Cell Cancer 1 Neoplasm Metastasis 1 Lymphatic Metastasis 1 Lung Neoplasms 1

Interventions

Cyclophosphamide 66 Dexamethasone 52 Lenalidomide 37 Peripheral Blood Stem Cell Transplantation 36 Rituximab 35 fludarabine phosphate 34 Bortezomib 30 Filgrastim 27 Etoposide 26 Cytarabine 25 Carboplatin 25 Busulfan 23 Radiotherapy 22 Melphalan 22 Gemcitabine 22 Cyclosporine 21 pomalidomide 20 fludarabine 20 Whole-Body Irradiation 20 Mycophenolic Acid 20 Paclitaxel 19 Methotrexate 18 Cisplatin 17 pembrolizumab 16 Calcium Dobesilate 16 Bevacizumab 16 venetoclax 15 Tacrolimus 14 Antilymphocyte Serum 14 Nivolumab 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02387099 2022-02-23

Desiree

GBG Forschungs GmbH

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡